JP2023531683A - ＣＥＢＰ－βアンタゴニストの投与及び使用方法 - Google Patents

ＣＥＢＰ－βアンタゴニストの投与及び使用方法 Download PDF

Info

Publication number
JP2023531683A
JP2023531683A JP2022579019A JP2022579019A JP2023531683A JP 2023531683 A JP2023531683 A JP 2023531683A JP 2022579019 A JP2022579019 A JP 2022579019A JP 2022579019 A JP2022579019 A JP 2022579019A JP 2023531683 A JP2023531683 A JP 2023531683A
Authority
JP
Japan
Prior art keywords
patient
pharmaceutical composition
administered
ebpβ
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022579019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531683A5 (https=
Inventor
カッペル，バリー・ジェイ
メルトゥカ，ジーン
ロトロ，ジミー・アンドリュー
ミシェル，ロバート・イー
ベクソン，アリス・スザンナ
Original Assignee
サピエンス・セラピューティクス・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サピエンス・セラピューティクス・インコーポレーテッド filed Critical サピエンス・セラピューティクス・インコーポレーテッド
Publication of JP2023531683A publication Critical patent/JP2023531683A/ja
Publication of JP2023531683A5 publication Critical patent/JP2023531683A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022579019A 2020-06-21 2021-06-21 ＣＥＢＰ－βアンタゴニストの投与及び使用方法 Pending JP2023531683A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063041990P 2020-06-21 2020-06-21
US202063041989P 2020-06-21 2020-06-21
US202063041986P 2020-06-21 2020-06-21
US202063041988P 2020-06-21 2020-06-21
US202063041991P 2020-06-21 2020-06-21
US63/041,988 2020-06-21
US63/041,991 2020-06-21
US63/041,986 2020-06-21
US63/041,989 2020-06-21
US63/041,990 2020-06-21
US202163172560P 2021-04-08 2021-04-08
US63/172,560 2021-04-08
PCT/US2021/038264 WO2021262604A2 (en) 2020-06-21 2021-06-21 Administration of cebp-beta antagonist and methods of use

Publications (2)

Publication Number Publication Date
JP2023531683A true JP2023531683A (ja) 2023-07-25
JP2023531683A5 JP2023531683A5 (https=) 2025-01-20

Family

ID=79281738

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579019A Pending JP2023531683A (ja) 2020-06-21 2021-06-21 ＣＥＢＰ－βアンタゴニストの投与及び使用方法

Country Status (14)

Country Link
US (1) US20230218717A1 (https=)
EP (1) EP4168033B1 (https=)
JP (1) JP2023531683A (https=)
KR (1) KR20230027054A (https=)
CN (1) CN115768458A (https=)
AU (1) AU2021297172B2 (https=)
BR (1) BR112022025880A2 (https=)
CA (1) CA3180559A1 (https=)
FI (1) FI4168033T3 (https=)
IL (1) IL299104A (https=)
MX (1) MX2022016478A (https=)
NZ (1) NZ795026A (https=)
PT (1) PT4168033T (https=)
WO (1) WO2021262604A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025532391A (ja) * 2022-10-07 2025-09-29 サピエンス・セラピューティクス・インコーポレーテッド Ｃ／ｅｂｐ－ベータアンタゴニスト及び免疫調節剤の使用
WO2024216238A2 (en) * 2023-04-13 2024-10-17 Sapience Therapeutics, Inc. Use of beta-catenin antagonist and immunomodulator
AU2024252321A1 (en) * 2023-04-13 2025-10-16 Sapience Therapeutics, Inc. Administration of a beta-catenin antagonist and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180237499A1 (en) * 2017-02-20 2018-08-23 Sapience Therapeutics, Inc. Cell-Penetrating ATF5 Polypeptides and Uses Thereof
JP2021508503A (ja) * 2018-01-03 2021-03-11 サピエンス・セラピューティクス・インコーポレーテッド Ａｔｆ５ペプチド多様体及びそれらの使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016516669A (ja) * 2013-02-22 2016-06-09 ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 転写因子ａｔｆ５の阻害により腫瘍細胞を阻害するための組成物および方法
US10899834B2 (en) * 2015-04-16 2021-01-26 H. Lundbeck A/S Anti-PACAP antibodies
WO2020033555A2 (en) * 2018-08-08 2020-02-13 The Trustees Of Columbia University In The City Of New York Dominant negative cebpb and cebpd proteins and methods of use for decreasing viability of neoplastic cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180237499A1 (en) * 2017-02-20 2018-08-23 Sapience Therapeutics, Inc. Cell-Penetrating ATF5 Polypeptides and Uses Thereof
JP2021508503A (ja) * 2018-01-03 2021-03-11 サピエンス・セラピューティクス・インコーポレーテッド Ａｔｆ５ペプチド多様体及びそれらの使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RES., vol. Vol.79 (13_Supplement), Abstract 2050, JPN6025032001, 2019, ISSN: 0005655270 *
SAPIENCE THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR ST101 IN ADVANCED CANCER INDIC, JPN6025032000, 2 June 2020 (2020-06-02), ISSN: 0005655269 *
SAPIENCE THERAPEUTICS RECEIVES UNITED KINGDOM AUTHORIZATION TO INITIATE A PHASE 1/2 TRIAL OF LEAD CA, JPN6025031999, 7 May 2020 (2020-05-07), ISSN: 0005655268 *

Also Published As

Publication number Publication date
WO2021262604A3 (en) 2022-02-17
CN115768458A (zh) 2023-03-07
KR20230027054A (ko) 2023-02-27
FI4168033T3 (fi) 2026-04-07
BR112022025880A2 (pt) 2023-01-10
EP4168033B1 (en) 2026-02-25
US20230218717A1 (en) 2023-07-13
EP4168033A2 (en) 2023-04-26
AU2021297172A1 (en) 2023-01-19
CA3180559A1 (en) 2021-12-30
AU2021297172B2 (en) 2025-01-30
EP4168033A4 (en) 2024-06-19
IL299104A (en) 2023-02-01
NZ795026A (en) 2026-03-27
PT4168033T (pt) 2026-03-24
MX2022016478A (es) 2023-02-01
WO2021262604A2 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
EP2421562B1 (en) Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
AU2021297172B2 (en) Administration of CEBPβ antagonist and methods of use
EP3228630A1 (en) Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
JP2014515748A (ja) ＢＣＬ９の安定化されたαへリックスを使用した、癌における調節解除されたＷｎｔシグナル伝達の標的化
KR102701695B1 (ko) 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도
JP2023531683A5 (https=)
JP2022553041A (ja) Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法
KR20250171308A (ko) 베타-카테닌 길항제의 투여 및 사용 방법
KR102508650B1 (ko) 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법
US12558400B2 (en) Method of treatment of soft tissue sarcoma with a peptide comrpising a PCNA interacting motif
WO2025110250A1 (ja) 改変ｍｆｇ－ｅ８タンパク質
AU2023356118A1 (en) Use of c/ebp-beta antagonist and immunomodulator
EP4694912A2 (en) Use of beta-catenin antagonist and immunomodulator
CA3230285A1 (en) Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
EA041148B1 (ru) Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20260203